Privia Health Group, Inc. (NASDAQ:PRVA) Shares holding was raised by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. increased its position in Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 4.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 245,137 shares of the company’s stock after buying an additional 10,146 shares during the period. Oppenheimer Asset Management Inc. owned about 0.21% of Privia Health Group worth $4,260,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have recently modified their positions in PRVA. Norges Bank bought a new stake in Privia Health Group in the fourth quarter valued at $27,959,000. First Light Asset Management LLC purchased a new stake in shares of Privia Health Group in the first quarter worth about $21,620,000. Riverbridge Partners LLC boosted its stake in Privia Health Group by 17.5% in the first quarter. Riverbridge Partners LLC now owns 5,399,662 shares of the company’s stock worth $105,779,000 after purchasing an additional 804,304 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Privia Health Group by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock valued at $259,740,000 after acquiring an additional 274,345 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Privia Health Group by 50.7% in the first quarter. Sei Investments Co. now owns 457,880 shares of the company’s stock valued at $8,970,000 after acquiring an additional 154,044 shares in the last quarter. 94.48% of shares are held by hedge funds and other institutional investors.

Insider buying and selling at Privia Health Group

In other news, CEO Parth Mehrotra sold 135,142 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $18.50, for a total transaction of $2,500,127.00. Following the transaction, the chief executive officer now directly owns 247,771 shares in the company, valued at $4,583,763.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Corporate insiders own 14.20% of the company’s shares.

Privia Health Group trading down 1.4%

Shares of Privia Health Group stock opened at $18.69 on Tuesday. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 124.60, a P/E/G ratio of 4.40 and a beta of 0.77. The company’s 50-day moving average price is $19.43, and its two-hundred-day moving average price is $18.73. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $24.35.

Privia Health Group (NASDAQ:PRVA – Get Your Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The business had revenue of $422.30 million for the quarter, compared to analyst estimates of $411.50 million. Privia Health Group had a net margin of 0.88% and a return on equity of 2.42%. The company’s revenue for the quarter was up 2.2% year over year. In the same period last year, the company earned $0.06 per share. As a group, equities research analysts predict that Privia Health Group, Inc. will post 0.16 EPS for the current year.

Analyst upgrades and downgrades

PRVA has been the subject of several analyst research reports. Robert W. Baird boosted their price objective on Privia Health Group from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, August 26th. Royal Bank of Canada restated an “outperform” rating and issued a $28.00 price objective on shares of Privia Health Group in a research note on Wednesday, August 14th. Baird RW upgraded shares of Privia Health Group to a “strong-buy” rating in a research note on Thursday, May 30th. Barclays reduced their target price on shares of Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Monday, May 20th. Finally, Evercore ISI reduced their price objective on shares of Privia Health Group from $23.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday. July 9. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com , Privia Health Group has an average rating of “Moderate Buy” and an average target price of $24.86.

Read our latest review of Privia Health Group

Privia Health Group company profile

(Free report)

Privia Health Group, Inc operates as a national physician credentialing company in the United States. The company partners with medical groups, health plans and health systems to optimize physician practices, improve patient experiences and reward physicians for providing care in in-person and virtual settings.

Further reading

Receive daily news and reviews for Privia Health Group – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Privia Health Group and related companies with MarketBeat.com’s FREE daily email newsletter.